Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 16, Issue 6, Pages 457-459
Case Report

Duloxetine Contributing to a Successful Multimodal Treatment Program for Peripheral Femoral Neuropathy and Comorbid ‘Reactive Depression’ in an Adolescent

Ludmyla Kachko,1,2 Shiri Ben Ami,1,3 Alon Liberman,1,4 Einat Birk,5 and Sefi Kronenberg4,6

1Chronic Pain Clinic, Pain Treatment Service, Tel Aviv University, Tel Aviv, Israel
2Department of Anesthesia, Tel Aviv University, Tel Aviv, Israel
3Physiotherapy Unit, Tel Aviv University, Tel Aviv, Israel
4Department of Psychological Medicine, Tel Aviv University, Tel Aviv, Israel
5Pediatric Heart Institute, Tel Aviv University, Tel Aviv, Israel
6Feinberg Child Study Center; Schneider Children’s Medical Center of Israel, Petah Tiqwa; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Copyright © 2011 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the United States, duloxetine has been approved for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and fibromyalgia in the adult population. Data regarding the use of duloxetine in the pediatric population, however, are very limited. Femoral nerve injury is a rare complication of cardiac catheterization. In the case described, duloxetine contributed to a successful multimodal treatment program for peripheral neuropathic pain due to femoral neuropathy in an adolescent with ‘reactive depression’ and conversion symptoms. To the best of the authors’ knowledge, the present article is only the third such report on this dual use of duloxetine in children and adolescents, and the first report of such treatment following femoral neuropathy induced by cardiac catheterization.